COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”

The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansoor, Salman, Kelly, Siobhan, Murphy, Kevin, Waters, Aine, Siddiqui, Nauman Saleem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194245/
https://www.ncbi.nlm.nih.gov/pubmed/32372857
http://dx.doi.org/10.1186/s41983-020-00177-0
_version_ 1783528314735951872
author Mansoor, Salman
Kelly, Siobhan
Murphy, Kevin
Waters, Aine
Siddiqui, Nauman Saleem
author_facet Mansoor, Salman
Kelly, Siobhan
Murphy, Kevin
Waters, Aine
Siddiqui, Nauman Saleem
author_sort Mansoor, Salman
collection PubMed
description The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis.
format Online
Article
Text
id pubmed-7194245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-71942452020-05-02 COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?” Mansoor, Salman Kelly, Siobhan Murphy, Kevin Waters, Aine Siddiqui, Nauman Saleem Egypt J Neurol Psychiatr Neurosurg Review The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis. Springer Berlin Heidelberg 2020-05-01 2020 /pmc/articles/PMC7194245/ /pubmed/32372857 http://dx.doi.org/10.1186/s41983-020-00177-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Mansoor, Salman
Kelly, Siobhan
Murphy, Kevin
Waters, Aine
Siddiqui, Nauman Saleem
COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
title COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
title_full COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
title_fullStr COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
title_full_unstemmed COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
title_short COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
title_sort covid-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194245/
https://www.ncbi.nlm.nih.gov/pubmed/32372857
http://dx.doi.org/10.1186/s41983-020-00177-0
work_keys_str_mv AT mansoorsalman covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow
AT kellysiobhan covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow
AT murphykevin covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow
AT watersaine covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow
AT siddiquinaumansaleem covid19pandemicandtheriskofinfectioninmultiplesclerosispatientsondiseasemodifyingtherapieswhatthebleepdoweknow

Ejemplares similares